Patents Issued in June 1, 2004
  • Patent number: 6743394
    Abstract: A case according to the present invention is used in a sintering process to produce a rare-earth magnet. The case includes: a body with an opening; a door for opening or closing the opening of the body; and supporting rods for horizontally sliding a sintering plate, on which green compacts of rare-earth magnetic alloy powder are placed. The supporting rods are secured inside the body. At least the body and the door are made of molybdenum.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: June 1, 2004
    Assignee: Sumitomo Special Metals Co., Ltd.
    Inventors: Akiyasu Oota, Tsuyoshi Wada, Katsumi Okayama
  • Patent number: 6743395
    Abstract: The present invention relates to composite metallic ultrafine particles which have excellent dispersion stability and can be produced on an industrial scale, and a process for producing the same, and a method and an apparatus for forming an interconnection with use of the same. A surface of a core metal produced from a metallic salt, a metallic oxide, or a metallic hydroxide and having a particle diameter of 1 to 100 nm is covered with an organic compound including a functional group having chemisorption capability onto the surface of the core metal.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: June 1, 2004
    Assignee: Ebara Corporation
    Inventors: Akira Fukunaga, Hiroshi Nagasawa, Kaori Kagoshima, Makiko Emoto
  • Patent number: 6743396
    Abstract: The present invention relates to a method for producing AlMn strips or sheets for producing components by soldering, wherein a precursor material is produced from a melt which contains (in weight-percent) Si: 0.3-1.2%, Fe: ≦0.5%, Cu: ≦0.1%, Mn: 1.0-1.8%, Mg: ≦0.3%, Cr+Zr: 0.05-0.4%, Zn: ≦0.1% , Ti: ≦0.1% , Sn: ≦0.15%, and unavoidable companion elements, whose individual amounts are at most 0.05% and whose sum is at most 0.15%, as well as aluminum as the remainder, wherein the precursor material is preheated at a preheating temperature of less than 520° C. over a dwell time of at most 12 hours, wherein the preheated precursor material is hot rolled into a hot strip using a final hot rolling temperature of at least 250° C., wherein the hot strip is cold rolled into a cold strip without intermediate annealing.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: June 1, 2004
    Assignee: Hydro Aluminium Deutschland GmbH
    Inventors: Pascal Wagner, Wolf-Dieter Finkelnburg, Dietrich Wieser, Manfred Mrotzek
  • Patent number: 6743397
    Abstract: The invention concerns a device for qualifying products containing volatile substances forming an analyte. The devices includes a measuring apparatus (2) provided with an enclosure (21a) and an electronic analyzing circuit (21b) for defining said analyte characteristics, a pumping system (30) for producing a vacuum inside said enclosure, a sampling chamber (16) wherein the analyte is introduced and a capillary (22) for connecting said chamber (16) to said enclosure (21a).
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: June 1, 2004
    Inventor: Thierry Zesiger
  • Patent number: 6743398
    Abstract: A serum/clot separation surface determination apparatus includes a test tube formed of a non-magnetic material containing a blood sample which is separated into a serum and a clot by a silicon separating medium, a detection coil fitted on an outer surface of the test tube, a measurement signal supply unit which supplies a measurement signal having a given frequency to the detection coil, a drive control unit which variably controls a relative position between the detection coil and the test tube in a longitudinal direction of the test tube by moving at least one of the detection coil and the test tube, a signal level detector which detects a level of the measurement signal that varies with the relative position, and a determination unit which determines a position of a sample separation surface obtained by the silicon separating medium, based on the level of the detected measurement signal.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: June 1, 2004
    Inventor: Teruaki Itoh
  • Patent number: 6743399
    Abstract: A microfluidic device which operates without the need for an external power source. The device includes a body structure, at least one microscale channel within the structure, a port for introducing fluid into the channel, and a power source internal to the structure for propelling the fluid through the channel. Various structures are described which embody the invention.
    Type: Grant
    Filed: October 6, 2000
    Date of Patent: June 1, 2004
    Assignee: Micronics, Inc.
    Inventors: Bernhard H. Weigl, Clinton L. Williams, Jon W. Hayenga, Ronald L. Bardell, Thomas E. Schulte
  • Patent number: 6743400
    Abstract: The present invention is directed to a sparger system provided for appropriately feeding reactant streams to fluidized bed reactors of hydrocarbon partial oxidation processes that are retrofitted to selectively recover and recycle unreacted hydrocarbons. As a result of the sparger system, the reactor productivity and selectivity is enhanced while employing only two spargers. Also, the capital cost required for retrofitting existing sparging equipment is minimized, while at the same time, the desired fluidization and catalyst oxidation characteristics are achieved without the formation of flammable mixtures within the sparging system.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: June 1, 2004
    Assignee: The BOC Group, Inc.
    Inventors: Ramakrishnan Ramachandran, Prabhu Balaraman
  • Patent number: 6743401
    Abstract: A distributor (9) for the equalization of flow rate of cyclones in closed cyclone systems installed in the interconnection of the cyclones of the disengager vessel of the gas-solid suspension of the fluid catalytic cracking (FCC) processes is described, that distributes the gases exiting the first stage cyclones so as to promote a desirable and uniform flow rate of said gases through said space, besides absorbing the relative movements between the cyclones caused by the differential thermal expansion. The distributor of the invention secures a homogeneous accommodation of the gas-solid suspension in a connecting pipe, allowing a uniform cyclone operation in the next stage, no matter the geometry of the riser-cyclone set or of the downer-cyclone set.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: June 1, 2004
    Assignee: Petroleo Brasileiro S.A.
    Inventor: Eduardo Cardoso De Melo Guerra
  • Patent number: 6743402
    Abstract: A purifier of a noxious gas is provided with structure for supplying a gas containing a noxious gas component, a buffer using a liquid which dissolves the noxious gas component in the supplied gas temporarily and later releases the dissolved noxious gas component, and structure for purifying the noxious gas component in the gas supplied from the buffer means. The liquid in the buffer dissolves the noxious gas component when the concentration of the noxious gas component in the supplied gas is high and releases the noxious gas component dissolved thus far when the concentration is low. When the noxious gas is ethylene oxide, water is used as the liquid.
    Type: Grant
    Filed: January 8, 2002
    Date of Patent: June 1, 2004
    Inventor: Kenzo Shimakawa
  • Patent number: 6743403
    Abstract: A process for the removal and causticisation of sodium oxalate and/or sodium sulphate from a Bayer process liquor containing sodium carbonate and one or both of sodium oxalate and sodium sulphate in an alumina refinery is described. The process is based on the observation that to efficiently causticise sodium oxalate solutions, it is first necessary to remove the aluminate ion from solution, optionally with recovery of the aluminate ion in some later step. This is effected by removing aluminate ions from the Bayer liquor through the formation of a carbonate-bearing hydrocalumite and/or sulphate-hearing hydrocalumite. The liquor may then be treated with sufficient lime to remove and causticise any residual carbonate ions and some or all of the oxalate ions present so that any reacted lime solids thus formed can be separated and safely disposed of.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: June 1, 2004
    Assignee: Worsley Alumina Pty. Ltd.
    Inventors: Steven P. Rosenberg, Wayne Tichbon, Darrel J. Wilson, Catherine A. Heath
  • Patent number: 6743404
    Abstract: A reactor for the catalytic oxidation of ammonia to form nitrogen oxides which has a noble metal gauze catalyst and a heat exchanger in that order in the direction of flow, a catalyst for the decomposition of N2O is located between the noble metal gauze catalyst and the heat exchanger and in a process for the catalytic decomposition of N2O in a gas mixture obtained in the preparation of nitric acid by catalytic oxidation of ammonia, where the N2O is decomposed catalytically over a catalyst of the decomposition of N2O, the hot gas mixture obtained from the catalytic oxidation of ammonia is brought to contact with the catalyst for the decomposition of N2O prior to subsequent cooling.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: June 1, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Volker Schumacher, Gert Bürger, Thomas Fetzer, Michael Baier, Michael Hesse
  • Patent number: 6743405
    Abstract: A sorbent material is provided comprising a material reactive with sulfur, a binder unreactive with sulfur and an inert material, wherein the sorbent absorbs the sulfur at temperatures between 30 and 200° C. Sulfur absorption capacity as high as 22 weight percent has been observed with these materials.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: June 1, 2004
    Assignee: The United States of America as represented by the United States Department of Energy
    Inventor: Ranjani Siriwardane
  • Patent number: 6743406
    Abstract: A family of discrete and uniformly sized silicon nanoparticles, including 1 (blue emitting), 1.67 (green emitting), 2.15 (yellow emitting), 2.9 (red emitting) and 3.7 nm (infrared emitting) nanoparticles, and a method that produces the family. The nanoparticles produced by the method of the invention are highly uniform in size. A very small percentage of significantly larger particles are produced, and such larger particles are easily filtered out. The method for producing the silicon nanoparticles of the invention utilizes a gradual advancing electrochemical etch of bulk silicon, e.g., a silicon wafer. The etch is conducted with use of an appropriate intermediate or low etch current density. An optimal current density for producing the family is ˜10 milli Ampere per square centimeter (10 mA/cm2). Higher current density favors 1 nm particles, and lower the larger particles.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: June 1, 2004
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Munir H. Nayfeh, Gennadey Belomoin, Satish Rao, Joel Therrien, Sahraoui Chaieb
  • Patent number: 6743407
    Abstract: A process for the production of hydrogen cyanide is provided, wherein hydrogen cyanide is synthesized by reacting methane or methane-containing natural gas, ammonia and oxygen-enriched air or oxygen in the presence of a catalyst comprising platinum or a platinum alloy; wherein the reactants are present in the following molar ratios [ O 2 ] [ O 2 + N 2 ] = 0.25 ⁢   ⁢ to ⁢   ⁢ 1.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: June 1, 2004
    Assignee: Roehm GmbH & Co. KG
    Inventors: Thomas Schaefer, Hermann Siegert
  • Patent number: 6743408
    Abstract: A method of producing carbon single wall nanotubes (SWNT) by CVD is disclosed. The SWNTs are grown on a metal-catalyzed support surface, such as a commercially available silicon tips for atomic force microscopes (AFM). The growth characteristics of the SWNTs can be controlled by adjusting the density of the catalyst and the CVD growth conditions. The length of the SWNTs can be adjusted through pulsed electrical etching. Nanotubes of this type can find applications in nanotubes structures with defined patterns and for nano-tweezers. Nano-tweezers may be useful for manipulating matter, such as biological material, on a molecular level.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: June 1, 2004
    Assignee: President and Fellows of Harvard College
    Inventors: Charles M. Lieber, Jason H. Hafner, Chin Li Cheung, Philip Kim
  • Patent number: 6743409
    Abstract: Novel methods for producing alkali metal fluorozincates, especially potassium fluorozincate. Products having defined particle size ranges are obtained depending on the sequence of introduction of the reactants alkali metal hydroxide, zinc oxide and hydrogen fluoride. The resulting alkali metal fluorozincates are particularly suitable for use as a fluxing agent or fluxing agent additive during brazing of aluminum or aluminum alloys and can be applied by wet or dry fluxing methods depending on the particle size of the alkali metal fluorozincate particles.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: June 1, 2004
    Assignee: Solvay Fluor and Derivative GmbH
    Inventors: Ulrich Seseke-Koyro, Andreas Becker, Joachim Frehse
  • Patent number: 6743410
    Abstract: A method is provided to inject liquid water into the normal stream of fuel, superheated air and superheated steam entering a primary reactor of a fuel processor. The injection location is in the steam supply line where superheated steam vaporizes a majority of the liquid water, preferably prior to injection into the primary reactor. Steam supplied by a vaporizer may temporarily lag desired steam production due to system up-power transients or startup conditions, coupled with vaporizer thermal lag time. Injection of liquid water overcomes this temporary deficit of steam. Additional air is also supplied as needed to improve reactance for a given steam volume/temperature. Injection rate or volume of the liquid water and air may also be based on one or more measured variables of the primary reactor.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: June 1, 2004
    Assignee: General Motors Corporation
    Inventor: Gary M. Robb
  • Patent number: 6743411
    Abstract: A composition of matter comprises a pathogen-targeting organic moiety which is conjugated to a radioisotope which has a half-life of less than 100 days. The composition can be synthesized by bringing together a radioisotope having a half life of less than 100 days with a greater than stoichiometric amount of a complexing agent so as to form a first mixture containing a reaction product between the radioisotope and the complexing agent; removing the excess complexing agent from the mixture; and bringing together the first reaction product and an antibody substance so as to form a second mixture containing a reaction product between the first reaction product and the antibody substance. The composition is deposited on a particulate substrate and is useful for treating infectious diseases caused by pathogens by passing the patients blood through a bed formed from the particles.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: June 1, 2004
    Assignee: RX/IBR Corporation
    Inventor: Arthur Dale Ericsson
  • Patent number: 6743412
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • Patent number: 6743413
    Abstract: Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 1, 2004
    Assignee: 3M Company
    Inventors: Robert K. Schultz, David W. Schultz, Martin J. Oliver, Robert A. Moris, Philip A. Jinks
  • Patent number: 6743414
    Abstract: The present invention relates to the treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form. The invention also relates to pharmaceutical inhalation compositions suitable for the treatment and prevention of bone diseases.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: June 1, 2004
    Assignee: Geneva Pharmaceuticals, Inc.
    Inventor: Nageswara R. Palepu
  • Patent number: 6743415
    Abstract: The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of lidocaine, verapamil, diltiazem, isometheptene, or lisuride. In a method aspect of the present invention, one of lidocaine, verapamil, diltiazem, isometheptene, or lisuride is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: June 1, 2004
    Assignee: ALEXZA Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Patent number: 6743416
    Abstract: Disclosed are sunscreen compositions comprising a combination of titanium dioxide and zinc oxide being present in a weight ratio of from about 10:1 to 1:10 and the total of said titanium dioxide and zinc oxide comprises greater than 60% by weight of the total composition. Also disclosed is a method for reducing sunburn on animals comprising the step of topically apply a composition comprising a combination of titanium dioxide and zinc oxide being present in a weight ratio of from about 10:1 to 1:10 and the total of said titanium dioxide and zinc oxide comprises greater than 60% by weight of the total composition onto exposed skin of the animal.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: June 1, 2004
    Inventor: Bonnie Riedl
  • Patent number: 6743417
    Abstract: A method of treating onychomycosis is described which includes administration of a topical formulation containing an effective amount of urea and an antioxidant to an infected area around a nail of a patient.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: June 1, 2004
    Assignee: Bradley Pharmaceuticals, Inc.
    Inventors: Bradley P. Glassman, Dileep Bhagwat, Daniel Glassman
  • Patent number: 6743418
    Abstract: A deodorant pad is disclosed. The deodorant pad would comprise a towelette which would be included within an aluminum foil package. Each towelette would be approximately two inches by two inches. Each towelette would be immersed in a solution of baby powder, baking soda, deodorant, and water. Because the towelette would be stored within the aluminum foil packet, the towelette would be capable of being stored for long periods of time until needed for use. The present invention would be transportable and would be disposable after use.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: June 1, 2004
    Inventors: Barbara Buford, Brittney Buford
  • Patent number: 6743419
    Abstract: A method of reducing the rate of mammalian hair growth includes topically applying a composition containing a sulfhydryl reactive compound to the skin.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: June 1, 2004
    Assignee: The Gillette Company
    Inventors: Douglas Shander, Gurpreet S. Ahluwalia, Diana Marks-Del Grosso
  • Patent number: 6743420
    Abstract: The disclosure of this invention relates to odor control and more particularly, to a process and composition whereby household, institutional and industrial odors are eliminated wherein these odors are incorporated in a variety of substrates or are emitted from industrial sludges. The odor control composition of this invention is a solution of Chloramine-T which may incorporate a suitable wetting agent. The solutions in this invention may further be buffered. The concentration of the Chloramine-T can be from about 0.5 to about 15 weight percent when used. The concentration of the wetting agent can be from about 0.1 to about 5%.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: June 1, 2004
    Assignee: H & S Chemical Company
    Inventor: David J. Schneider
  • Patent number: 6743421
    Abstract: The present invention relates to a method of removing organic acid an/or organic amines odors from aqueous systems by treating the aqueous system or the atmosphere adjacent to the aqueous system with a solution of a substantially sulfonate free, anionic kraft pine lignin.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: June 1, 2004
    Assignee: GE Betz, Inc.
    Inventors: Stephen R. Vasconcellos, Terry L. Robbins
  • Patent number: 6743422
    Abstract: The present invention concerns variants and chemical derivates of keratinocyte growth factor-2 (KGF-2) protein. Also disclosed are nucleic acid molecules encoding such variants, as well as methods for using such variants and chemical derivates to stimulate epithelial cell proliferation.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: June 1, 2004
    Assignee: Amgen, Inc.
    Inventors: Linda Owers Narhi, Timothy David Osslund
  • Patent number: 6743423
    Abstract: The invention relates to the use of adeno-associated viruses for decreasing the radiotherapy-induced or chemotherapy-induced resistance in patients who suffer from a cancer which is to be treated by radiotherapy or chemotherapy.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: June 1, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Mangus Von Knebel-Doeberitz, Petra Klein-Bauernschmitt, Harald Zur Hausen, Jörg Schlehofer
  • Patent number: 6743424
    Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: June 1, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Patent number: 6743425
    Abstract: The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient are disclosed.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: June 1, 2004
    Inventor: Kazuwa Nakao
  • Patent number: 6743426
    Abstract: The present invention provides a method of treatment of heparin-induced thrombocytopenia (HIT) with protein C. The claimed invention provides a needed therapy for a potentially serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Charles Jack Fisher, Sau-Chi Betty Yan
  • Patent number: 6743427
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&bgr; and antibodies binding to the same.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 1, 2004
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Patent number: 6743428
    Abstract: The present invention provides a novel angiogenesis inhibitor, LK68 whose amino acid sequence is identical with the human apolipoprotein (a) kringle domains IV36, IV37 and V38, a cDNA sequence encoding the LK68, a recombinant expression vector comprising the cDNA, a recombinant microorganism transformed with the recombinant expression vector and a novel use of the LK68 as an anticancer agent and a method for treating angiogenesis-mediated disease. LK68, LK6, LK7 and LK8 exhibit inhibitory activities on the cultured endothelial cell proliferation as well as on the endothelial cell migration. LK68 and its single kringles also inhibit the normal development of capillaries in the chick embryo chorioallantoic membrane (CAM). It was also showed that systemic administration of LK68 causes the inhibition of primary tumor growth, which is correlated with a suppression of tumor-induced angiogenesis.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: June 1, 2004
    Assignee: Mogam Biotechnology Research Institute
    Inventors: Jihoon Chang, Jang Seong Kim, Eun Jeong Park, Jung-sun Yum, Soo-Il Chung
  • Patent number: 6743429
    Abstract: The present invention relates to the use of calcitonin gene-related peptide (CGRP) in the prevention and alleviation of asthmatic symptoms. In contrast to other therapeutic agents now in use, CGRP combines both bronchoprotector and anti-inflammatory properties. Furthermore, it prevents both early and late phase bronchial responses associated with an asthma attack and its effective dose is small enough that undesirable haemodynamic side effects are not present.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: June 1, 2004
    Assignee: Sherbrooke University
    Inventor: Alain Cadieux
  • Patent number: 6743430
    Abstract: Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: June 1, 2004
    Inventors: Richard E. Parizek, Lonny E. Vlieger, Sharon A. Bryant, Stuart K. Nibbelink, Michael J. McGinley
  • Patent number: 6743431
    Abstract: A substantially pure capsular exopolysaccharide adhesin of coagulaso-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and mono-clonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by noso-comial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: June 1, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Gerald B. Pier
  • Patent number: 6743432
    Abstract: A hydrophilic membrane having a low adsorptivity for a protein is disposed, as an interface, on a side to be contacted with a skin, and a drug such as a physiologically active peptide is transdermally delivered by iontophoresis. The membrane has an adsorptivity for a protein of not greater than 10 &mgr;g/cm2. The thickness of the membrane is about 10 to 200 &mgr;m, and the porosity of the membrane is about 60 to 90%. Such membrane includes a hydrophilized fluororesin membrane, a hydrophilized polysulfone membrane and a hydrophilized cellulose derivative membrane.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: June 1, 2004
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Shigeo Yanai, Katsumi Iga, Yukihiro Matsumoto, Naruhito Higo
  • Patent number: 6743433
    Abstract: Acne is treated or prevented by the topical application of compositions containing an alkanolamine such as dimethylaminoethanol, tyrosine, and a sulfur ingredient such as lipoic acid or glutathione. Adjunct ingredients such as fatty acid esters of ascorbic acid, e.g., ascorbyl palmitate and &agr;-hydroxy acids may be included in the formulations. Compositions of the invention may be used alone, or, in many preferable embodiments, in combination with conventional acne medications such as anti-acne products containing salicylic acid, benzoyl peroxide, or a retinoid. In these embodiments, alkanolamine compositions of the invention are applied to affected skin areas first, and then a conventional acne medication is applied. This maximizes the efficacy of the treatment while minimizing skin irritation caused by conventional medications.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: June 1, 2004
    Inventor: Nicholas V. Perricone
  • Patent number: 6743434
    Abstract: The invention, in part, relates to skin care or hair care compositions containing a source of carbon dioxide. The carbon dioxide is conveniently entrained in a gel-network, or liquid crystalline phase, immediately prior to skin or hair application. A substantial portion of the carbon dioxide will be lost from the product upon application to the skin or hair. However, a sufficient amount of carbon dioxide will remain in the product to stimulate oxygen flow to the outer layers of the skin with the apparent retardation of skin aging. The present invention also relates to the field of hair treatment and particularly to the removal of chemically bound residues and mineral deposits from hair. Hair may act as a sink for environmental minerals and heavy metals. In addition to undesirable changes in color and appearance, environmental minerals may have an adverse effect on chemical hair treatments. Mineral deposits in tap water may strip away highlights, darkening hair to a brassier hue.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: June 1, 2004
    Inventors: Larry D. Lundmark, Wallace R. Hlavac
  • Patent number: 6743435
    Abstract: Methods are provided for processing and dispersing animal tissues that involve exposing processed (e.g., decellularized) tissue to an acylating agent, wherein the ratio of acylating agent to wet tissue weight is about 0.003:1 or less. Preferably, decellularized tissue is exposed to an amount of the acylating agent of about 0.1% to about 0.3% of wet tissue weight for a time ranging from about 30 seconds to about 10 minutes. A dispersed tissue matrix is produced that has a high degree of resistance to digestion by non-collagenase proteases, such as trypsin. In order to produce sufficiently high yields of these trypsin-resistant compositions, the processed tissue is preferably cryomilled to increase its surface area prior to acylation. The dispersed acylated decellularized tissue may be in the form of an injectable composition that can be introduced into tissue of a subject.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: June 1, 2004
    Assignee: Collagen Matrix Technologies, Inc.
    Inventors: Dale P. DeVore, Peter D. Ciarametaro
  • Patent number: 6743436
    Abstract: An anesthetic composition for intravenous injection, comprising propofol (2,6-diisopropylphenol) and Poloxamer POLOXAMER (Polyoxyethylene-polyoxypropylene copolymer) as surfactant is disclosed. The composition optionally can contain at least one co-surfactant selected from the group consisting of SOLUTOL HS 15 (Macrogol-15 Hydroxystearate), egg lecithin, LABRASOL (Polyoxy capryllic glyceride), polyoxy 10-oleyl-ether, TWEEN (polyoxyethylene sorbitan fatty acid esters), ethanol and polyethylene glycol. Because the composition is usually prepared in the form of an oil-in-water microemulsion having a particle size of 100 nm and below, it has superior technical effects in that it is thermodynamically stable and can be aseptically filtered to prevent microorganism contamination. Moreover, the composition is readily prepared so that side effects such as embolism, hyperlipidemia, etc. can be minimized.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: June 1, 2004
    Assignee: Kuhnil Pharm. Co., Ltd.
    Inventors: Hyuk-Koo Lee, Ji-Young Jin, Hoon Cho
  • Patent number: 6743437
    Abstract: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: June 1, 2004
    Assignee: Allergan, Inc.
    Inventors: Orest Olejnik, Patrick M. Hughes, John S. Kent
  • Patent number: 6743438
    Abstract: Optical lenses and methods of preparing the same, in which an active material encapsulated in resin capsules is impregnated in said lens, adjacent an optical surface thereof. The active material may be a coloring material for producing a printed color pattern in the iris or other areas of the lens, or it may be a therapeutic agent.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: June 1, 2004
    Assignee: PBH, Inc.
    Inventors: Ashok R. Thakrar, Bradley K. Overmyer, William E. Meyers
  • Patent number: 6743439
    Abstract: Aqueous pharmaceutical solution compositions preserved with a cationic preservative and comprising a cationic drug and a sulfonated styrene/maleic anhydride copolymer are disclosed. The compositions are particularly well suited for topical ophthalmic use, but may also be used as topically administrable otic or nasal compositions.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: June 1, 2004
    Assignee: Alcon, Inc.
    Inventors: Ernesto J. Castillo, Wesley Wehsin Han, Huixiang Zhang, Ronald F. Berry
  • Patent number: 6743440
    Abstract: A composition, preferably used to reduce methane formation in a ruminant, wherein the composition is a combination of a polycyclic quinone compound and an ionophore compound.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: June 1, 2004
    Assignee: Arkion Life Sciences LLC
    Inventor: Kenneth E. Ballinger, Jr.
  • Patent number: 6743441
    Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: June 1, 2004
    Assignee: Watson Pharmaceuticals, Inc.
    Inventors: Steven W. Sanders, Charles D. Ebert
  • Patent number: 6743442
    Abstract: Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: June 1, 2004
    Assignee: Euro-Celtique, S.A.
    Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang, David Sackler
  • Patent number: 6743443
    Abstract: The present invention provides an intraoral quickly disintegrating tablet containing a phosphodiesterase inhibitor having an effect of improving the erectile dysfunction and a method for manufacturing the tablet. The present invention also provides an intraoral quickly disintegrating tablet containing a slightly soluble pharmaceutical agent having an improved solubility and a method for manufacturing the tablet. That is, it is an intraoral quickly disintegrating tablet containing a cyclic GMP phosphodiesterase inhibitor and a saccharide, and a method for manufacturing the tablet.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: June 1, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Hisao Furitsu, Akira Kato, Takayuki Ohwaki, Masanobu Yasui